GSK PLC GSK shares rallied 1.06% to £13.34 Monday, on what proved to be an all-around favorable trading session for the stock ...

Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

A multidisciplinary team, including McGregor Coxall, Haworth Tompkins, Studio Egret West, dRMM, Buro Happold, and ...

For much of her early career, Shobie Ramakrishnan called Silicon Valley home. GSK’s chief data and technology officer (CDTO) ...

GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a price target of ...

GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK announced that its B7-H3-targeted antibody-drug conjugate, GSK’227, has received ...

A design team including Haworth Tompkins, Metropolitan Workshop, dRMM and Studio Egret West is drawing up a major ...

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...

GSK PLC GSK shares inched down 0.34% to £13.30 Friday, on what proved to be an all-around grim trading session for the stock ...